NeoGenomics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
NeoGenomics, Inc. (NEO) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $16.48 per share as of 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2023-02-24
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $16.48.
- 2021-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $25.46.
- 2020-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $15.21.
- 2018-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $9.97; Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed $7.63.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2022-12-31 | $16.48 10-K · filed 2023-02-24 | |
| 2021-12-31 | $25.46 10-K · filed 2022-02-25 | |
| 2020-12-31 | $15.21 10-K · filed 2021-02-25 | |
| 2018-12-31 | $9.97 10-K · filed 2020-02-28 | $7.63 10-K · filed 2019-02-26 |
| 2017-12-31 | $6.52 10-K · filed 2018-03-13 | |
| 2014-12-31 | $2.04 10-K · filed 2015-03-03 | |
| 2013-12-31 | $1.22 10-K · filed 2014-02-24 | |
| 2012-12-31 | $1.02 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |